Literature DB >> 24253023

High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.

W Kraan1, M van Keimpema1, H M Horlings1, E J M Schilder-Tol1, M E C M Oud1, L A Noorduyn2, P M Kluin3, M J Kersten4, M Spaargaren1, S T Pals1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24253023     DOI： 10.1038/leu.2013.348

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.

Authors:  Manuel Montesinos-Rongen; Elzbieta Godlewska; Anna Brunn; Otmar D Wiestler; Reiner Siebert; Martina Deckert
Journal:  Acta Neuropathol       Date:  2011-10-22       Impact factor: 17.088

2.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

3.  Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.

Authors:  Georg Lenz; R Eric Davis; Vu N Ngo; Lloyd Lam; Thaddeus C George; George W Wright; Sandeep S Dave; Hong Zhao; Weihong Xu; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Wing C Chan; Louis M Staudt
Journal:  Science       Date:  2008-03-06       Impact factor: 47.728

Review 4.  Primary testicular lymphoma.

Authors:  S S Ahmad; S F Idris; G A Follows; M V Williams
Journal:  Clin Oncol (R Coll Radiol)       Date:  2012-03-17       Impact factor: 4.126

5.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Patricia Sheehy; Robert J Manning; Christopher J Patterson; Christina Tripsas; Luca Arcaini; Geraldine S Pinkus; Scott J Rodig; Aliyah R Sohani; Nancy Lee Harris; Jason M Laramie; Donald A Skifter; Stephen E Lincoln; Zachary R Hunter
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

6.  First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.

Authors:  Umberto Vitolo; Annalisa Chiappella; Andrés J M Ferreri; Maurizio Martelli; Ileana Baldi; Monica Balzarotti; Chiara Bottelli; Annarita Conconi; Henry Gomez; Armando Lopez-Guillermo; Giovanni Martinelli; Francesco Merli; Domenico Novero; Lorella Orsucci; Vincenzo Pavone; Umberto Ricardi; Sergio Storti; Mary K Gospodarowicz; Franco Cavalli; Andreas H Sarris; Emanuele Zucca
Journal:  J Clin Oncol       Date:  2011-06-06       Impact factor: 44.544

Review 7.  Pathogenesis of human B cell lymphomas.

Authors:  Arthur L Shaffer; Ryan M Young; Louis M Staudt
Journal:  Annu Rev Immunol       Date:  2012-01-06       Impact factor: 28.527

8.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Authors:  R Eric Davis; Vu N Ngo; Georg Lenz; Pavel Tolar; Ryan M Young; Paul B Romesser; Holger Kohlhammer; Laurence Lamy; Hong Zhao; Yandan Yang; Weihong Xu; Arthur L Shaffer; George Wright; Wenming Xiao; John Powell; Jian-Kang Jiang; Craig J Thomas; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Nathalie A Johnson; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Dennis D Weisenburger; Wing C Chan; Susan K Pierce; Louis M Staudt
Journal:  Nature       Date:  2010-01-07       Impact factor: 49.962

9.  Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.

Authors:  Alberto Gonzalez-Aguilar; Ahmed Idbaih; Blandine Boisselier; Naïma Habbita; Marta Rossetto; Alice Laurenge; Aurélie Bruno; Anne Jouvet; Marc Polivka; Clovis Adam; Dominique Figarella-Branger; Catherine Miquel; Anne Vital; Hervé Ghesquières; Rémy Gressin; Vincent Delwail; Luc Taillandier; Olivier Chinot; Pierre Soubeyran; Emmanuel Gyan; Sylvain Choquet; Caroline Houillier; Carole Soussain; Marie-Laure Tanguy; Yannick Marie; Karima Mokhtari; Khê Hoang-Xuan
Journal:  Clin Cancer Res       Date:  2012-07-26       Impact factor: 12.531

10.  Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

Authors:  Mara Compagno; Wei Keat Lim; Adina Grunn; Subhadra V Nandula; Manisha Brahmachary; Qiong Shen; Francesco Bertoni; Maurilio Ponzoni; Marta Scandurra; Andrea Califano; Govind Bhagat; Amy Chadburn; Riccardo Dalla-Favera; Laura Pasqualucci
Journal:  Nature       Date:  2009-05-03       Impact factor: 49.962
View more
  28 in total

1.  FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells.

Authors:  Martine van Keimpema; Leonie J Grüneberg; Michal Mokry; Ruben van Boxtel; Jan Koster; Paul J Coffer; Steven T Pals; Marcel Spaargaren
Journal:  Blood       Date:  2014-09-29       Impact factor: 22.113

2.  Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Ariz Akhter; Noraidah Masir; Ghaleb Elyamany; Kean-Chang Phang; Etienne Mahe; Ali Matar Al-Zahrani; Meer-Taher Shabani-Rad; Douglas Allan Stewart; Adnan Mansoor
Journal:  J Neurooncol       Date:  2014-11-13       Impact factor: 4.130

3.  MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma.

Authors:  C Fernández-Rodríguez; B Bellosillo; M García-García; B Sánchez-González; E Gimeno; M C Vela; S Serrano; C Besses; A Salar
Journal:  Leukemia       Date:  2014-06-06       Impact factor: 11.528

Review 4.  Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond.

Authors:  Richard Rosenquist; Andreas Rosenwald; Ming-Qing Du; Gianluca Gaidano; Patricia Groenen; Andrew Wotherspoon; Paolo Ghia; Philippe Gaulard; Elias Campo; Kostas Stamatopoulos
Journal:  Haematologica       Date:  2016-09       Impact factor: 9.941

5.  Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.

Authors:  Kazuyuki Shimada; Kenichi Yoshida; Yasuhiro Suzuki; Chisako Iriyama; Yoshikage Inoue; Masashi Sanada; Keisuke Kataoka; Masaaki Yuge; Yusuke Takagi; Shigeru Kusumoto; Yasufumi Masaki; Takahiko Ito; Yuichiro Inagaki; Akinao Okamoto; Yachiyo Kuwatsuka; Masahiro Nakatochi; Satoko Shimada; Hiroaki Miyoshi; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Yusuke Shiozawa; Yasuhito Nannya; Asako Okabe; Kei Kohno; Yoshiko Atsuta; Koichi Ohshima; Shigeo Nakamura; Seishi Ogawa; Akihiro Tomita; Hitoshi Kiyoi
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

6.  Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

Authors:  Michail S Lionakis; Kieron Dunleavy; Mark Roschewski; Brigitte C Widemann; John A Butman; Roland Schmitz; Yandan Yang; Diane E Cole; Christopher Melani; Christine S Higham; Jigar V Desai; Michele Ceribelli; Lu Chen; Craig J Thomas; Richard F Little; Juan Gea-Banacloche; Sucharita Bhaumik; Maryalice Stetler-Stevenson; Stefania Pittaluga; Elaine S Jaffe; John Heiss; Nicole Lucas; Seth M Steinberg; Louis M Staudt; Wyndham H Wilson
Journal:  Cancer Cell       Date:  2017-05-25       Impact factor: 31.743

7.  PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.

Authors:  Lakshmi Nayak; Fabio M Iwamoto; Ann LaCasce; Srinivasan Mukundan; Margaretha G M Roemer; Bjoern Chapuy; Philippe Armand; Scott J Rodig; Margaret A Shipp
Journal:  Blood       Date:  2017-03-29       Impact factor: 22.113

8.  MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.

Authors:  Fatima Hamadeh; Stephen P MacNamara; Nadine S Aguilera; Steven H Swerdlow; James R Cook
Journal:  Mod Pathol       Date:  2014-09-12       Impact factor: 7.842

Review 9.  [Classification of malignant lymphomas. Current situation].

Authors:  K Koch; W Klapper
Journal:  Internist (Berl)       Date:  2016-03       Impact factor: 0.743

10.  Targetable genetic features of primary testicular and primary central nervous system lymphomas.

Authors:  Bjoern Chapuy; Margaretha G M Roemer; Chip Stewart; Yuxiang Tan; Ryan P Abo; Liye Zhang; Andrew J Dunford; David M Meredith; Aaron R Thorner; Ekaterina S Jordanova; Gang Liu; Friedrich Feuerhake; Matthew D Ducar; Gerald Illerhaus; Daniel Gusenleitner; Erica A Linden; Heather H Sun; Heather Homer; Miyuki Aono; Geraldine S Pinkus; Azra H Ligon; Keith L Ligon; Judith A Ferry; Gordon J Freeman; Paul van Hummelen; Todd R Golub; Gad Getz; Scott J Rodig; Daphne de Jong; Stefano Monti; Margaret A Shipp
Journal:  Blood       Date:  2015-12-23       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.